Abstract: The present disclosure relates to a device that includes an irregular network of interconnected ridges in physical contact with a planar substrate and a perovskite layer, where the planar substrate include a support layer and a first charge selective contact layer, the first charge selective contact layer is positioned between the support layer and the interconnected ridges, each ridge includes a second charge selective contact layer and an insulating layer, the insulating layer is positioned between the first charge selective contact layer and the second charge selective contact layer, and the perovskite layer substantially covers the plurality of interconnected ridges and the underlying planar substrate.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: Disclosed herein are systems for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-CoV-2 virus and/or other infectious agents that may be travelling within aerosols.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: Apparatus, systems, methods and articles are described to prepare and track medications and medication containers as they are prepared, administered to patients and, in some cases, disposed of. Information such as medication type, concentration, and volume are associated with medication containers during preparation and this information can later be consumed/utilized when administering the medication from a container to a patient. Disposing of any remaining medication can also be tracked.

Abstract: Disclosed herein are mechanical collars comprising a first connecting component and a second connecting component adjoined to one another. The second connecting component may comprise two substantially circular passages, wherein the inner diameter of the first substantially circular passage is larger than the outer diameter of the second substantially circular passage. Also disclosed herein are systems for mitigating the risk of transmission of infectious disease, such as in a healthcare provider's office, comprising mechanical collars as described herein, protective apparatuses, and a mechanical arm such as, without limitation, an articulating mechanical arm. Also disclosed herein are associated methods of mitigating risk of transmission of infectious disease utilizing the mechanical collars and related systems described herein.

Abstract: Apparatus, systems, methods and articles are described to prepare and track medications and medication containers as they are prepared, administered to patients and, in some cases, disposed of. Information such as medication type, concentration, and volume are associated with medication containers during preparation and this information can later be consumed/utilized when administering the medication from a container to a patient. Disposing of any remaining medication can also be tracked.

Abstract: An electrode assembly for a myoelectric prosthesis allowing at least partial decoupling of the movement of the at least one electrode from the electrode housing case and from the prosthesis socket through the mounting of the at least one electrode using at least one biasing element. This allows the at least one electrode to be forced into contact with the patient in the target area using a moveable pressure application structure reducing/eliminating socket motion artifacts because the pressure is transferred toward the target area but the at least one electrode is not otherwise constrained to minimise or avoid the at least one electrode being dragged across the target area through the mounting to the prosthesis socket which causes socket motion artifacts.

Abstract: Disclosed herein are protective apparatuses for minimizing the risk of transmission of SARS-CoV-2 and other infectious diseases between individuals in close proximity to one another. Said apparatuses may comprise a receiving component comprising a first aperture comprising a series of flanges; as well as a substantially transparent shield component. Protective apparatuses of the present disclosure may be used to protect dentists and other healthcare workers from transmission of infectious agents through aerosols and through transmission of droplets and other bodily fluids that may contain infectious agents and likewise may be used to protect patients in the same manner. Also disclosed herein are systems comprising such protective apparatuses installed to a substantially cylindrical suctioning device such as a vacuum hose or operatively attached to an articulating mechanical arm.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment. removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Abstract: A valve has a housing defining an inlet and an outlet and a cavity therebetween which receives a valve seat. The valve seat defines a slot which receives a gate. The valve seat is sealingly engaged with the housing, the gate sealingly engages the valve seat and is movable within the slot between an open and a closed position using an actuator. An opening in the housing provides access to the cavity. The valve seat may be removed from the housing through the opening by attaching the valve seat to the gate, thereby attaching the valve seat to the actuator, and withdrawing the gate from the housing using the actuator.

Abstract: A utensil dispenser including a reservoir that stores utensils and front and rear pedestals in contact with a next utensil. The pedestals contain a plurality of utensils within the reservoir. A gravity feed ramp moves the next utensil to an access port of the utensil dispenser. The utensil dispenser includes an actuator operably connected to a drive pin or other drive mechanism. The actuator is configured to halt a dispensing utensil at a ready position based upon contact between the dispensing utensil and the actuator. In the ready position, a handle portion of the dispensing utensil is accessible via the access port. The drive mechanism is configured to contact the next utensil. The actuator is configured to move the drive mechanism to move the next utensil to clear the front pedestal to release the next utensil from the reservoir onto the gravity feed ramp when the dispensing utensil is dispensed.